You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said it made changes to address the pandemic that allowed it to submit its Parsortix cell-sorting system to the FDA for use in metastatic breast cancer.
COVID-19-related business contributed $288 million in revenues during the quarter, offsetting a 6 percent year-over-year decline in non-COVID-19-related revenues.
GenMark said it placed 70 net ePlex analyzers in Q3 and ended the quarter with a global installed base of more than 720 ePlex analyzers.
Qiagen said that growth in the quarter was primarily driven by COVID-19 testing products and improving customer demand for other products.
The company's acquisitions of Thrive Early Detection and Base Genomics are meant to accelerate its development of a liquid biopsy multi-cancer screening test.
The company also acquired DNA methylation analysis firm Base Genomics for $410 million and said it plans to raise $869 million in a direct stock offering.
Clinical test volume and requisitions received each grew about 2 percent year over year, while the average revenue per test fell 3 percent.
Total revenues were $3.90 billion, up from $2.93 billion in the third quarter of 2019, and above the consensus Wall Street estimate of $3.63 billion.
For the half year ended Sept. 30, Yourgene booked £8.2 million ($10.7 million) in revenues, up from £7.8 million during the same period last year.
The firm said that its core business, excluding COVID-19 clinical testing revenues, returned to positive organic growth in the quarter.